Differences in Risk of Revision and Mortality Between Total and Unicompartmental Knee Arthroplasty. The Influence of Hospital Volume by Arias-de la Torre, J et al.
Accepted Manuscript
Differences in risk of revision and mortality between total and unicompartmental knee
arthroplasty. The influence of hospital volume
Jorge Arias-de la Torre, MSc, Jose M. Valderas, MD PhD, Jonathan Evans, MD,
Vicente Martín, MD PhD, Antonio J. Molina, MD PhD, Laura Muñoz, MSc, Miquel
Pons-Cabrafiga, MD PhD, Mireia Espallargues, MD PhD, on behalf of the Catalan
Arthroplasty Register Steering Committee (RACat)
PII: S0883-5403(19)30091-9
DOI: https://doi.org/10.1016/j.arth.2019.01.046
Reference: YARTH 57026
To appear in: The Journal of Arthroplasty
Received Date: 29 October 2018
Revised Date: 18 January 2019
Accepted Date: 18 January 2019
Please cite this article as: Arias-de la Torre J, Valderas JM, Evans J, Martín V, Molina AJ, Muñoz
L, Pons-Cabrafiga M, Espallargues M, on behalf of the Catalan Arthroplasty Register Steering
Committee (RACat), Differences in risk of revision and mortality between total and unicompartmental
knee arthroplasty. The influence of hospital volume, The Journal of Arthroplasty (2019), doi: https://
doi.org/10.1016/j.arth.2019.01.046.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Differences in risk of revision and mortality between total and unicompartmental 
knee arthroplasty. The influence of hospital volume. 
 
 
Jorge Arias-de la Torre MSc 1,2,3, Jose M Valderas MD PhD4, Jonathan Evans MD 4,5, 
Vicente Martín MD PhD 2,3, Antonio J Molina MD PhD 3, Laura Muñoz MSc1,6, 
Miquel Pons-Cabrafiga MD PhD 7, Mireia Espallargues MD PhD 1,6, on behalf of the 
Catalan Arthroplasty Register Steering Committee (RACat).  
 
1
 Agency for Heath Quality and Assessment of Catalonia (AQuAS) 
2
 CIBER Epidemiology and Public Health (CIBERESP), Madrid Spain. 
3Institute of Biomedicine (IBIOMED), University of Leon, León, Spain 
4Health Services and Policy Research Group, University of Exeter Medical School, Exeter, 
UK 
5Royal Devon and Exeter NHS Foundation Trust, Exeter, UK 
6Health Services Research on Chronic Patients Network (REDISSEC), Madrid, Spain 
7Sant Rafael Hospital, Barcelona, Barcelona, Spain. 
 
Corresponding author: 
Jorge Arias-de la Torre 
Agency for Health Quality and Assessment of Catalonia (AQuAs) 
Carrer de Roc Boronat, 81-95 (second floor) | 08005 Barcelona  
Tel. +34 935513886  
jariasdelatorre@gencat.cat 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
CONDFLICT OF INTERESTS: All authors declare they have no competing interests 
ROLE OF FUNDING SOURCE: The present study was funded by CIBERESP as part of 
the aid for short internships granted to Jorge Arias-de la Torre. 
ACKNOWLEDGEMENTS: We acknowledge Kayla Smith and Olga Martinez for their 
support in performing the study, and CIBER Epidemiology and Public Health (CIBERESP) 
for its funding 
ETHICAL APPROVAL: The present project was be developed in the framework of the 
Catalan Arthroplasty Register (RACat). Due to the nature of the data used to address the 
objectives and the belonging of the RACat to the Catalan Health System as a public health 
registry, it is not necessary an ethical approval. To guaranty the confidentiality of the 
patients according to the Spanish en European current regulation on data protection, the 
data are anonymised and continuously supervised by the steering committee of the RACat. 
This committee is composed by experts both from the orthopaedic surgery services of the 
different hospitals involved in data collection, as from the Catalan Health Service 
(CatSalut), the Catalan Society of Orthopaedic Surgery and Traumatology (SCCOT), and 
the Agency for Health Quality and Assessment of Catalonia (AQuAS). 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Differences in risk of revision and mortality between total and unicompartmental 1 
knee arthroplasty. The influence of hospital volume. 2 
ABSTRACT 3 
Background: The volume of arthroplasties performed in a hospital by year has an 4 
influence on the outcomes of Total Knee Arthroplasty (TKA) and Unicompartmental Knee 5 
Arthroplasty (UKA). The aims of this study are: 1) to evaluate and compare the risk of 6 
revision and mortality of TKA and UKA; and 2) to assess if hospital volume is related to 7 
differences in revision risk and mortality. Methods: All individuals recorded in the Catalan 8 
Arthroplasty Register between 1/1/2005 and 31/12/2016, diagnosed with osteoarthritis, 9 
undergoing cemented TKA and UKA were included. A propensity score matching method 10 
was used to obtain comparable cohorts, including 2,374 matched prostheses overall. 11 
Hospital volume was considered as a dichotomous variable (lower/higher). Descriptive 12 
analyses were done prior to and after matching. Risks of revision and mortality at 30 days, 13 
90 days, 1, 3 and 5 years were calculated and competing risks models and Cox models were 14 
fitted. Results: For the population as a whole, higher risk of revision (SHR 1.98; 95%CI: 15 
1.25-3.17) was found in UKA than in TKA but higher mortality was not. Considering the 16 
volume groups, significantly higher risk of revision in UKA than TKA was found in the 17 
lower volume group only (SHR: 1.95; 95%CI: 1.11-3.44). No differences in mortality 18 
between TKA and UKA were found in either group. Conclusions: Mortality and revision 19 
rates after TKA and UKA at higher volume hospitals are similar.  UKAs performed at 20 
lower volume hospitals have higher revision rates.  Volume-dependent specialization thus 21 
might help to reduce revision and mortality after surgery. 22 
 23 
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 26 
INTRODUCTION 27 
Decisions on type of implant choice for knee arthroplasty should consider the evidence for 28 
all available implant-specific outcomes. Current literature suggests that Unicompartmental 29 
Knee Arthroplasty (UKA) may be associated with a higher rate of revision than Total Knee 30 
Arthroplasty (TKA), but with similar mortality rates [1–7]. In some studies, these results 31 
have been attributed, among other factors, to an imbalance in the characteristics of the 32 
population operated on, as well as to the hospital where the surgery was performed.  33 
It is well-established that the decision regarding type of surgery should depend on an 34 
extensive evaluation of a patient’s characteristics, since populations undergoing TKA, 35 
versus those having UKA, are generally not comparable. Patients undergoing UKA usually 36 
have fewer comorbidities and are less demanding, in surgical terms, than those having TKA 37 
[2,8,9]. These differences in patient characteristics make it challenging to compare surgical 38 
outcomes like mortality and the risk of prosthesis revision between TKA and UKA and 39 
could lead to biased results and incorrect conclusions since the baseline characteristics of 40 
patients undergoing these procedures are dissimilar. To solve this problem, propensity-41 
score matching methods have moved a step forward in comparing populations in 42 
observational studies [10,11], which could lead to obtaining comparable patient populations 43 
of TKA and UKA, at least in terms of their baseline characteristics, thus allowing more 44 
precise comparisons to be made. 45 
Another group of variables with a possible relationship to the risk of revision is hospital 46 
characteristics. Taking these characteristics into account, some register-based studies have 47 
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suggested that the volume of arthroplasties performed in a hospital by year is particularly 48 
relevant due to its influence on surgical outcomes [12–16]. This volume could have an 49 
influence on the outcomes, depending on the type of surgery the study focused on, and 50 
might be especially pertinent in UKA [13,15]. As previously found, hospitals performing a 51 
higher volume of UKA by year might have better results in terms of revision, and similar 52 
results in terms of mortality compared with those shown in lower volume hospitals. 53 
Slightly less of a difference in TKA over UKA has also been shown between higher and 54 
lower volume hospitals in risk of revision, with higher rates of revision among lower 55 
volume hospitals [12,16]. The volume-related differences in mortality in TKA are unclear, 56 
and might be influenced by differences in the populations operated on in lower and higher 57 
volume hospitals.  58 
Therefore, in this framework and after obtaining comparable TKA and UKA populations, 59 
the aims of the present study are: 1) to evaluate and compare the risk of revision and 60 
mortality of matched TKA and UKA cohorts; and 2) to assess if the hospital volume is 61 
related to differences in revision and mortality between TKA and UKA. 62 
MATERIAL AND METHODS 63 
Data and study population 64 
For the present study, data from the Catalan Arthroplasty Register (RACat) and the 65 
Minimum Basic Dataset at Hospital Discharge (MBDS-HD) were used. The RACat is a 66 
population-based arthroplasty registry that has collected information about hip and knee 67 
arthroplasty procedures performed in the Catalan region since 2005. The registry includes 68 
51 out of 56 public hospitals performing knee arthroplasty surgery in Catalonia, with a 69 
completeness of about 90% for primary arthroplasties and about 70% for revision 70 
procedures. The MBDS-HD is a mandatory population-based registry that compiles 71 
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information about procedures and morbidities for the entire population attended to in 72 
Catalan Hospitals. Its dataset includes information about different aspects of the 73 
hospitalization process, such as diagnosis and other factors related to patients and surgery 74 
like comorbidity, hospital discharge data and hospital admission data.   75 
To develop the proposed objectives, all individuals recorded in the Catalan Arthroplasty 76 
Register (RACat) between 1/1/2005 and 31/12/2016, with a primary diagnosis of 77 
osteoarthritis, undergoing cemented UKA (n=1,210) or cemented TKA (n=38,032 78 
posterior-cruciate retaining, posterior-cruciate sacrificed and posterior stabilised) were 79 
included in the study population. Patients with a diagnosis for the primary procedure other 80 
than Osteoarthritis (OA), those with other types of knee arthroplasty, and those whose 81 
prosthesis had a cementless, hybrid or inverse hybrid fixation were excluded. After 82 
matching, a total of 2,374 patients, 1,187 patients for each type of intervention, remained in 83 
the study to perform the comparative analyses between UKA and TKA outcomes in the 84 
whole population. 85 
Study variables 86 
Two main outcomes were considered: mortality and risk of revision for any reason. A 87 
revision arthroplasty was defined as any procedure involving removal, exchange or addition 88 
of any implant part. Additionally, for competing risks models, the death of the patient was 89 
considered as a competing risk, i.e. an event that changes the likelihood that the main event 90 
occurs. 91 
The main exposure variable considered was the type of arthroplasty (TKA and UKA).  92 
The volume of procedures, defined as a dichotomous variable (higher and lower), was 93 
considered as the absolute frequency of a specific type of arthroplasty performed in each 94 
hospital for each year of the study period prior to matching. The cut-off point for lower 95 
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volume was fixed at 10 procedures for UKA and 100 procedures for TKA, based on the 96 
lower volume groups for UKA and TKA observed in previous literature [13,15,16], and the 97 
population distribution within the volume groups. The same hospital could contribute to a 98 
different volume group depending on the year and number of procedures performed. 99 
The following confounders were taken into account for propensity score matching: sex 100 
(male and female), age (in years, defined as a continuous variable), number of 101 
comorbidities from the Elixhauser index, year of intervention (categorized: 2005-2006, 102 
2007-2008, 2009-2010, 2011-2012 and 2013-2016), type of hospital (high technology, 103 
reference, regional and other type or not specified), type of admission (Emergency, 104 
scheduled and other types) and healthcare region (Barcelona, Girona, Catalunya Central, 105 
Camp de Tarragona, Lleida, Terres de l’Ebre, Alt Pirineu i Aran and other healthcare 106 
region or not specified).  107 
Data analysis  108 
Descriptive analyses of the population’s characteristics were done. A matching method 109 
based on propensity score was used to obtain comparable populations from the main 110 
exposure. The score was calculated considering arthroplasty type (UKA or TKA) as the 111 
exposure variable, and including the following confounders: sex, age, number of 112 
comorbidities (Elixhauser), year of the primary intervention (continuous), type of hospital, 113 
type of admission and healthcare region. Matching between UKA and TKA was 1:1 114 
without replacement, and included 2,374 matched prostheses overall (1,187 of each type). 115 
Differences in UKA and TKA populations at the bivariable level were assessed before and 116 
after matching using Chi-square tests and Mann-Whitney U tests for age, due to its non-117 
normal distribution. Mortality and risk of revision rates at 30 days, 90 days and 1, 3 and 5 118 
years were obtained using the Kaplan-Meier method, and Cox regression models were 119 
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fitted to assess differences in mortality between TKA and UKA. Incidence of revision was 120 
calculated taking the competing risk of death into account. The risk of revision was 121 
estimated by summing up to t S(t-1) * h'(t), where S(t-1) is the Kaplan-Meier estimate of 122 
the overall survival function and h'(t) is the cause-specific hazard at the time t. In addition, 123 
to evaluate differences in the risk of revision, Competing Risks models considering death as 124 
the competing event were implemented. From these models, hazard ratios (HR) for 125 
mortality, sub-hazard ratios (SHR) for revision and their 95% Confidence Interval (95%CI) 126 
were obtained. To account for the possible effect of infection as the cause of revision, all 127 
competing risks models were adjusted for the cause of revision. Additionally, to assess the 128 
influence of hospital volume on the risk of revision, all analyses were stratified by volume 129 
group. The stratified matched samples included 1,472 patients in the higher volume group 130 
(736 UKA and TKA) and 632 in the lower volume group (316 UKA and TKA). Statistical 131 
significance of the study variables was evaluated using a Likelihood Ratio test for Cox 132 
models and a Wald test for Competing Risks models. The significance level was fixed at 133 
α=0.05 and all analyses were carried out using the statistical software Stata v.14 [17]. 134 
RESULTS 135 
Comparison of patient characteristics 136 
Table 1 shows the characteristics of the study population before and after matching. 137 
Statistically significant (p<0.001) differences between the UKA and the TKA populations 138 
in all study variables were found, except in circumstances of hospital admission. After 139 
matching, none of these differences remained statistically significant. When taking patient 140 
characteristics into account by volume groups (Table 2), prior to matching, statistically 141 
significant differences in all study variables were found, except in the type of hospital 142 
admission and, in the lower volume group, in the year of the primary intervention and in 143 
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median follow-up. None of these differences remained significant in any group after 144 
matching. After matching, 18 hospitals’ patients contributed to the higher volume group for 145 
TKA and 4 for UKA; and in the lower volume group the contribution was 42 for TKA and 146 
29 for UKA. 147 
Risk of revision, mortality and the influence of hospital volume 148 
Table 3 shows that the risk of revision for TKA was 0.1% at 30 days, 0.3% at 90 days, 149 
0.4% at 1 year, 2.9% at 3 years and 4.2% at 5 years, while for UKA, no revision was 150 
performed at 30 days follow-up, and it was 0.1% at 90 days, 1.3% at 1 year, 5.5% at 3 151 
years, and 6.6% at 5 years . The mortality for TKA was <0.1% at 30 days, 0.1% at 90 days, 152 
0.5% at 1 year, 3.0% at 3 years and 4.1% at 5 years, while for UKA it was <0.1% at 30 153 
days, 0.2% at 90 days, 0.3% at 1 year, 2.3% at 3 years and 3.0% at 5 years, as shown in 154 
Figure 1. Additionally, Table 3 shows a significant adjusted revision risk of SHR of 1.98 155 
(95% CI: 1.25-3.17) for UKA compared to TKA (the reference category) in a Competing 156 
Risks model, and a non-significant adjusted HR of 0.74 (95% CI: 0.46-1.21) for mortality 157 
in a Cox model.  158 
Table 4 shows the risk of revision (Figure 2) and mortality rates (Figure 3) for higher 159 
volume and lower volume hospitals. Higher volume hospitals performing TKA had a 160 
higher, but not statistically significant, risk of revision than UKA (SHR: 1.36; 95% CI: 161 
0.57-3.21), while in lower volume hospitals, UKA had a higher, statistically significant, 162 
risk of revision than TKA (SHR: 1.95; 95% CI: 1.11-3.44). Non-statistically significant 163 
differences were found in mortality between UKA and TKA, independent of hospital 164 
volume (HR higher volume: 0.83, 95% CI: 0.43-1.60; HR lower volume: 0.49, 95% CI: 165 
0.21-1.15), with lower rates among UKA than among TKA, particularly in the lower 166 
volume group.    167 
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DISCUSSION 168 
Our study shows that UKA has a higher risk of revision when compared to TKA. However, 169 
when the annual volume of UKA and TKA procedures performed in a specific hospital is 170 
taken into account, this difference is not seen. While hospitals conducting a higher volume 171 
of UKA have reduced their revision rate to that commensurate with or even lower than 172 
TKA levels, hospitals conducting a lower volume of UKA have a clearly increased revision 173 
rate over hospitals conducting a low volume of TKA. Additionally, our study shows that 174 
these volume-related differences do not exist in terms of mortality since the rates in UKA 175 
are lower but not significant like in TKA.    176 
Regarding the risk of revision, after discarding differences in baseline characteristics of the 177 
UKA and TKA populations and the stratification done, it is reasonable to attribute the 178 
differences found to the volume of the hospital where the arthroplasty was performed. In 179 
this sense, it should be emphasized that, after obtaining comparable populations, a higher 180 
risk of revision was found in UKA over TKA for the entire population and especially in the 181 
lower volume group, since the risk of revision in UKA was more than 2.5 times higher than 182 
in TKA. Moreover, in the higher volume group, a lower but statistically non-significant risk 183 
of revision was found for UKA compared to TKA. These results support, for the entire 184 
population, those obtained from one previous study in which the risk of revision in UKA 185 
was higher than in TKA [7], and are comparable to the evidence obtained by other studies 186 
that focused on UKA only [13,15,18]. These studies show that lower volume hospitals had 187 
worse results when compared to higher volume hospitals. Taking into account the 188 
mortality, no statistically significant differences between TKA and UKA were found in the 189 
population as a whole or when the analyses were stratified by volume group. Nevertheless, 190 
despite that the differences found were non-significant, we should highlight that the 191 
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mortality rates were lower for UKA than for TKA in all groups studied. These results show 192 
new evidence supporting the hypothesis pointed out by previous research about the 193 
similarity in results in terms of mortality between UKA and TKA  [1,8,10]. Thus, to carry 194 
out studies with larger sample sizes, longer follow-up times and taking hospital volume into 195 
account, might be adequate to confirm the abovementioned hypothesis. Finally, though 196 
there are outcomes that were not considered in our research, previous studies have shown 197 
lower rates of complications and readmission and better results in terms of Patient Related 198 
Outcome Measures (PROMs) in UKA than TKA [1,8,9,19]. These studies have also shown 199 
that UKA could be a cost-effective option, additionally suggesting that these outcomes 200 
might be better in higher volume hospitals than in lower volume hospitals. Therefore, all 201 
proposed evidence suggests TKA might be a suitable decision for patients undergoing knee 202 
arthroplasty, both in higher and lower volume hospitals, while UKA is appropriate only in 203 
higher volume hospitals. Furthermore, due to the evidence-based consequences that 204 
implanting UKA in lower volume performing hospitals might have, from the results in our 205 
context, it might be pertinent to limit UKA procedures to hospitals that can guarantee that a 206 
higher volume of this type of procedure is performed.  207 
There are some limitations in this study that need to be discussed. First, limitations related 208 
to the number of volume groups and the differences in the number of contributing hospitals. 209 
In our context, only four hospitals were included in the UKA higher volume hospital group 210 
when the cut-off point was fixed at 10 procedures per year. However, despite this 211 
limitation, we can assume that higher volume hospitals performing TKA and UKA are 212 
highly specialized in this these types of procedures and therefore can be considered as 213 
suitable candidates for comparison. Besides, crossover between hospital volume groups 214 
was not taken into account. Nevertheless, as observed in hospitals participating in the 215 
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RACat [5], this change of volume group was, in most cases, an increasing or decreasing 216 
trend of hospital activity. In terms of the limitations related to the study variables, the 217 
indication for surgery was unknown and could be different between TKA and UKA. 218 
Furthermore, surgeon related variables, like differences in surgeons’ expertise by volume 219 
group, were not taken into account. Despite this, given that reporting this data to the RACat 220 
has been mandatory since 2017, we expect to be able to take these aspects into account in 221 
the upcoming years. In addition, we should emphasize the limitation related to including all 222 
implant sub-types. Though some registers and studies show differences between sub-types, 223 
these differences are unclear [3–5,20,21]. Besides, including all models together could be 224 
advantageous when establishing conclusions at the population level. Finally, we want to 225 
stress that the completeness of the information, particularly in revision arthroplasties, is not 226 
perfect, but we expect an improvement in these rates in the upcoming years since hospital 227 
participation in the registry is now mandatory. Moreover, it might be advantageous to 228 
explore the influence of the volume of procedures by hospital with longer follow-up times, 229 
as well as with other outcomes like complications, readmissions or PROMs [1,19]. Future 230 
research considering long-term results, other outcomes and volume-dependent 231 
specialization might be useful in reducing the burden of morbidity and revision of knee 232 
arthroplasties and improving patient-specific decision-making.  233 
CONCLUSIONS 234 
After overcoming the possible bias related to differences in patients’ characteristics, our 235 
results show that in Catalonia there are currently differences in the risk of revision between 236 
UKA and TKA, but not in mortality. The evidence presented in this article shows that the 237 
seemingly poorer results in terms of risk of revision of UKA when compared to TKA, are 238 
closely related to the volume of UKA procedures performed in a specific hospital. 239 
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Therefore, to improve results in terms of revisions, we suggest performing TKA in both 240 
higher and lower volume hospitals, while UKA should be done only in hospitals 241 
performing a higher annual volume of this type of procedure.  242 
 243 
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Table 1. Characteristics of the whole study sample before and after matching 
 
Crude sample Matched sample 
 
TKA UKA p value TKA UKA p value 
Number of patients 38,032 1,210 
 
1,187 1,187 
 Number of hospitals 49 31  45 31  
Median follow-up (IQR) 4.6 (4.9) 3.1 (4.0) <0.001 3.3 (4.1) 3.1 (4.0) 0.326 
Median age in years (IQR) 73.4 (10.1) 67.7 (12.4) <0.001 68.5 (10.9) 67.9 (12.2) 0.515 
Median number of comorbidities 
(min-max)* 1 (0-7) 1 (0-5) <0.001 1 (0-5) 1 (0-5) 0.555 
Sex (male) 10,526 (27.7%) 478 (39.5%) <0.001 454 (38.3) 460 (38.8%) 0.800 
Year of the primary surgery  
 <0.001   0.922 
2005-2007 5,114 (13.5%) 77 (6.4%) 
 
84 (7.1%) 77 (6.5%) 
 2008-2009 6,030 (15.9%) 143 (11.8%) 
 
131 (11.0%) 141 (11.9%) 
 2010-2011 8,175 (21.5%) 169 (14.0%)  175 (14.7%) 169 (14.2%)  
2012-2013 7,723 (20.3%) 283 (23.4%)  285 (24.0%) 279 (23.5%)  
2005-2010 10,990 (28.9%) 538 (44.5%)  512 (43.1%) 521 (43.9%)  
Circumstances of hospital 
admission   0.488   - 
Emergency 44 (0.1%) - 
 
- - 
 Scheduled 37,987 (99.9%) 1,210 (100%) 
 
1,187 (100%) 1,187 (100%) 
 Other types 1 (<0.1%) - 
 
- - 
 Type of hospital   
 <0.001   0.968 
High technology  15,551 (40.9%) 834 (68.9%) 
 
816 (68.7%) 811 (68.3%) 
 Reference hospital 14,578 (38.3%) 207 (17.1%) 
 
206 (17.4%) 207 (17.4%) 
 Regional hospital 7,794 (20.5%) 169 (14.0%) 
 
165 (13.9%) 169 (14.2%) 
 Other type or not specified 109 (0.29%) - 
 
- - 
 Healthcare region  
 <0.001   0.522 
Barcelona 23,657 (62.2%) 1,022 (84.5%)  1,021 (86.0%) 1,001 (84.3%)  
Girona 5,728 (15.1%) 51 (4.2%)  45 (3.8%) 51 (4.3%)  
Catalunya Central 3,287 (8.6%) 68 (5.6%)  70 (5.9%) 68 (5.7%)  
Camp de Tarragona 2,881 (7.6%) 48 4.0%)  35 (3.0%) 47 (4.0%)  
Lleida 1,098 (2.9%) - 
 
- - 
 Terres de l’Ebre 744 (2.0%) 5 (0.4%)  7 (0.6%) 5 (0.4%)  
Alt Pirineu i Aran 521 (1.4%) 15 (1.2%)  9 (0.8%) 15 (1.3%)  
Other region or not specified 116 (0.3%) 1 (0.1%) 
 
- - 
 
TKA: Total Knee Arthroplasty; UKA: Unicompartmental Knee Arthroplasty; p value: from Chi-square test and Mann-Whitney U test; IQR: 
Interquartile Range; Min-max: minimum-maximum; * Comorbidities from those included in the Elixhauser Index. 
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Table 2. Characteristics of the study sample stratified by type of surgery and volume groups after matching 
 
Higher volume crude sample Higher volume matched sample Lower volume crude sample Lower volume matched sample 
 
TKA UKA p value TKA UKA p 
value TKA UKA p value TKA UKA p value 
Number of patients 23,790 846  736 736  14,242 364 
 
316 316 
 Number of hospitals 30 4  18 4  47 31  42 29  
Median follow-up (IQR) 4.3 (4.8) 2.7 (2.8) <0.001 3.1 (2.7) 3.2 (2.7) 0.428 5.3 (5.0) 5.1 (5.3) 0.336 5.2 (4.8) 5.2 (4.3) 0.976 
Median age in years (IQR) 73.4 (10.2) 69.6 (11.5) <0.001 70.8 (10.0) 70.3 (10.6) 0.327 73.4 (10.0) 63.0 (10.6) <0.001 65.0 (12.2) 64.5 (10.3) 0.515 
Median number of 
comorbidities (min-max)* 1 (0-7) 1 (0-5) <0.001 1 (0-4) 1 (0-5) 0.450 1 (0-6) 1 (0-4) <0.001 1 (0-4) 1 (0-4) 0.548 
Sex (male) 6,552 (27.5%) 339 (40.1%) <0.001 259 (35.2%) 279 (37.9%) 0.279 3,974 (27.9%) 139 (38.2%) <0.001 127 (40.2%) 110 (34.8%) 0.162 
Year of the primary surgery   <0.001   0.520   0.066   0.535 
  2005-2007 2,750 (11.6%) 15 (1.8%)  14 (1.9%) 15 (2.0%)  2,364 (16.6%) 62 (17.0%) 
 
41 (13.0%) 54 (17.1%) 
 
  2008-2009 3,476 (14.6%) 66 (7.8%)  56 (7.6%) 63 (8.6%)  2,554 (17.9%) 77 (21.2%) 
 
69 (21.8%) 71 (22.5%) 
 
  2010-2011 5,040 (21.2%) 98 (11.6%)  92 (12.5%) 73 (9.9%)  3,135 (22.0%) 71 (19.5%)  61 (16.3%) 63 (19.9%)  
  2012-2013 4,910 (20.6%) 198 (23.4%)  160 (21.7%) 174 (23.6%)  2,813 (19.8%) 85 (23.4%)  75 (23.7%) 70 (22.2%)  
  2014-2016 7,614 (32.0%) 469 (55.4%)  414 (56.3%) 411 (55.8%)  3,376 (23.7%) 69 (19.0%)  70 (22.2%) 58 (18.4%)  
Circumstances of hospital 
admission   0.411   -   0.717   - 
  Emergency 19 (0.1%) -  - -  25 (0.2%) - 
 
- - 
 
  Scheduled 23,771 (99.9%) 846 (100%)  736 (100%) 736 (100%)  14,216 (99.8%) 364 (100%) 
 
316 (100%) 316 (100%) 
 
  Other types - -  - -  1 (<0.1%) - 
 
- - 
 Type of hospital    <0.001   0.940   <0.001   0.820 
  High technology  6,432 (27.9%) 731 (86.4)  618 (84.0%) 621 (84.4%)  9,119 (64.0%) 103 (28.3%) 
 
94 (29.8%) 101 (32.0%) 
 
  Reference hospital 10,026 (42.1%) 13 (1.5%)  12 (1.6%) 13 (1.8%)  4,552 (32.0%) 194 (53.3%) 
 
171 (54.1%) 164 (51.9%) 
 
  Regional hospital 7,226 (30.4%) 102 (12.1%)  106 (14.4%) 102 (13.9%)  568 (4.0%) 67 (18.4%) 
 
51 (16.1%) 51 (16.1%) 
 
  Other type or not specified 106 (0.5%) -     3 (<0.1%) - 
 
- - 
 Healthcare region   <0.001   0.519   <0.001   0.329 
  Barcelona 17,424 (73.2%) 815 (96.3%)  715 (97.2%) 706 (95.9%)  6,233 (43.8%) 207 (56.9%)  146 (46.2%) 169 (53.5%)  
  Girona 281 (1.2%) 1 (0.1%)  1 (0.1%) 1 (0.1%)  463 (3.3%) 4 (1.1%)  9 (2.9%) 4 (1.3%)  
  Catalunya Central 701 (3.0%) 1 (0.1%)  - 1 (0.1%)  2,180 (15.3) 47 (12.9)  46 (14.6%) 42 (13.3%)  
  Camp de Tarragona 1,512 (6.4%) 19 (2.3%)  16 (2.2%) 19 (2.3%)  1,775 (12.5%) 49 (13.5%)  48 (15.2%) 45 (14.2)  
  Lleida 700 (2.9%) -  - -  398 (2.8%) . 
 
12 (3.8%) 14 (4.4%) 
 
  Terres de l’Ebre 3,067 (12.9%) 9 (1.1%)  4 (0.5%) 9 (1.2%)  2,661 (18.7%) 42 (11.5%)  55 (17.4%) 42 (13.3%)  
  Alt Pirineu i Aran 30 (0.1% -  - -  491 (3.5%) 15 (4.1%)  12 (3.8%) 14 (4.4%)  
  Other region or not specified 75 (0.3%) 1 (0.1%)  - -  41 (0.3%) . 
 
. . 
 TKA: Total Knee Arthroplasty; UKA: Unicompartmental Knee Arthroplasty 
p value: from Chi-square test and Mann-Whitney U test; IQR: Interquartile Range; Min-max: minimum-maximum; * Comorbidities from those included in the Elixhauser Index. 
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Table 3: Risk of revision and mortality from all causes, using Kaplan-Meier (entire population after matching) 
  
TKA UKA  
  
n Fail % 95% CI n Fail % 95% CI SHR/HR  (95% CI) 
Risk of revision 
        
1.98  
(1.25-3.17) 
30 days 1182 1 0.08 0.01-0.47 1185 0 NC NC  
90 days 1151 2 0.25 0.07-0.71 1158 1 0.09 0.01-0.47  
1 year 1024 1 0.35 0.12-0.85 1010 13 1.28 0.74-2.09  
3 years  636 22 2.86 1.91-4.11 604 37 5.48 4.13-7.09  
5 years 354 7 4.08 2.83-5.57 337 6 6.54 4.99-8.36  
Mortality 
        
0.74  
(0.46-1.21) 
30 days 1182 0 NC NC 1185 1 0.08 0.01-0.60  
90 days 1151 1 0.09 0.01-0.60 1158 1 0.17 0.04-0.68  
1 year 1024 4 0.45 0.19-1.09 1010 1 0.26 0.08-0.79  
3 years  636 21 3.00 2.04-4.41 604 16 2.27 1.44-3.57  
5 years 354 6 4.14 2.90-5.89 337 4 2.98 1.97-4.50  
TKA: Total Knee Arthroplasty; UKA: Unicompartmental Knee Arthroplasty 
n: number of primary procedures at risk remaining at the cut-off point; Fail: number of events (revision/dead); % 
cumulative risk of revision/mortality; 95% CI: 95% Confidence Interval; SHR/HR: Sub Hazard ratio for risk of revision 
from competing risks models/ Hazard ratio for mortality from Cox models. 
NC: Not Calculable. 
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Table 4: Risk of revision and mortality TKA vs UKA stratified by volume groups (after matching) 
  TKA UKA  
  
n Fail  % 95% CI n Fail  % 95% CI SHR/HR  (95% CI) 
Risk of revision    
Higher Volume         1.36 (0.57-3.21) 
   30 days 733 1 0.13 0.01-0.74 736 0 NC NC  
   90 days 707 2 0.41 0.12-1.14 716 1 0.14 0.01-0.75  
   1 year 605 7 1.47 0.76-2.62 606 5 0.88 0.37-1.83  
   3 years  304 9 3.42 2.10-5.22 306 8 2.50 1.41-4.09  
   5 years 139 8 6.35 4.15-9.17 136 1 2.96 1.65-4.88  
Lower volume 
        
1.95 
(1.11-3.44) 
   30 days 314 0 NC NC 314 0 NC NC  
   90 days 305 0 NC NC 309 0 NC NC  
   1 year 286 0 NC NC 282 7 2.39 1.06-4.65  
   3 years  235 8 3.07 1.44-5.70 225 22 10.54 7.26-14.51  
   5 years 153 4 4.86 2.64-8.07 159 4 12.19 8.62-16.42  
Mortality  
Higher Volume         0.83 (0.43-1.60) 
   30 days 733 0 NC NC 736 0 NC NC  
   90 days 707 0 NC NC 716 1 0.14 0.02-0.97  
   1 year 605 4 0.62 0.23-1.64 606 1 0.28 0.07-1.11  
   3 years  304 9 2.56 1.47-4.43 306 9 2.09 1.15-3.78  
   5 years 139 4 4.09 2.47-6.73 136 3 3.21 1.85-5.53  
Lower volume         0.49 (0.21-1.15) 
   30 days 314 0 NC NC 314 1 0.32 0.04-2.23  
   90 days 305 0 NC NC 309 0 0.32 0.04-2.23  
   1 year 286 2 0.67 0.17-2.67 282 0 0.32 0.04-2.23  
   3 years  235 2 1.41 0.53-2.71 225 4 2.04 0.85-4.86  
   5 years 153 5 3.97 2.05-7.59 159 1 2.48 1.12-5.46  
TKA: Total Knee Arthroplasty; UKA: Unicompartmental Knee Arthroplasty 
n: number of primary procedures at risk remaining at the cut-off point; Fail: number of events (revision/dead); % 
cumulative risk of revision/mortality; 95% CI: 95% Confidence Interval; SHR/HR: Sub Hazard ratio for risk of revision 
from competing risks models/ Hazard ratio for mortality from Cox models 
NC: Not Calculable. 
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